Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

While a majority of the mammalian genome is transcribed to RNA, mounting evidence indicates that only a minor proportion of these transcriptional products are actually translated into proteins. Since the discovery of the first non-coding RNA (ncRNA) in the 1980s, the field has gone on to recognize ncRNAs as important molecular regulators of RNA activity and protein function-knowledge of which has stimulated the expansion of a scientific field that quests to understand the role of ncRNAs in cellular physiology, tissue homeostasis, and human disease. Although our knowledge of these molecules has significantly improved over the years, we have limited understanding of their precise functions, protein interacting partners, and tissue-specific activities. Adding to this complexity, it remains unknown exactly how many ncRNAs there are in existence. The increased use of high-throughput transcriptomics techniques has rapidly expanded the list of ncRNAs, which now include classical ncRNAs [e.g., ribosomal RNAs (rRNAs), transfer RNAs (tRNAs)], microRNAs (miRNAs), and long ncRNAs (lncRNAs). In addition, splicing byproducts of protein-coding genes and ncRNAs, so called circular RNAs (circRNAs), are now being investigated. Because there is substantial heterogeneity in the functions of ncRNAs, we have summarized the current state of knowledge regarding the functions of ncRNAs in heart, lungs, and skeletal muscle. This review highlights the pathophysiologic relevance of these ncRNAs in the context of human cardiovascular, pulmonary, and muscle diseases.